Immuron (ASX:IMC) has provided an update on its U.S. clinical programs for Travelan and IMM-529, confirming progress in its regulatory engagement with the U.S. Food and Drug Administration (FDA) and outlining next steps following minor protocol updates. …
Immuron provides update on U.S. clinical trials for Travelan and IMM-529
October 31, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
Telix files for European approval of brain cancer imaging candidate TLX101-Px
February 18, 2026 - - Australian Biotech -
IDT signals turnaround as revenue rises and losses narrow under strategic reset
February 18, 2026 - - Latest News -
Nyrada advances lead candidate into mid-stage trial as momentum builds across programs
February 18, 2026 - - Australian Biotech -
Novo Nordisk backs community-led initiative that aims to transform life for Logan’s children
February 18, 2026 - - Latest News -
CSL and Lilly strike strategic deal to advance promising anti-inflammatory therapy
February 18, 2026 - - Latest News -
Targeted blood cancer treatments proposed for funding in New Zealand
February 18, 2026 - - Latest News -
Percheron targets next wave of immunotherapy with novel VISTA checkpoint candidate
February 18, 2026 - - Australian Biotech